Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 20, 2021
Cash flows from operating activities:
Net loss	$ (8,494)	$ (7,162)	$ (7,422)	$ (15,656)	$ (63,223)	$ (63,223)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization				385		304
Gain on disposal of equipment	(69)			(70)	(44)	(44)
Noncash interest expense				0		22
Share-based compensation				3,018		1,856
Amortization of premium and discount on marketable securities				110		0
Charge for in-process R&D	0			0	50,618	50,618
ROU asset amortization				548		518
Changes in operating assets and liabilities:
Prepaid expenses and other current assets				64		(200)
Accounts payable				5,588		(502)
Accrued expenses				(5,987)		(398)
Operating lease liability				(542)		(495)
Net cash used in operating activities				(12,542)		(11,544)
Cash flows from investing activities:
Purchases of property and equipment				(131)		(424)
Purchases of marketable securities				(105,779)		0
Asset acquisition costs				0		(318)
Proceeds from sale of equipment				176		115
Net cash used in investing activities				(105,734)		(627)
Cash flows from financing activities:
Repayment of borrowings				0		(3,750)
Net cash used in financing activities				0		(3,750)
Net change in cash, cash equivalents and restricted cash				(118,276)		(15,921)
Cash, cash equivalents and restricted cash at beginning of period		$ 144,514	$ 47,339	144,514	$ 47,339	47,339
Cash, cash equivalents and restricted cash at end of period	$ 26,238			26,238		31,418
Supplemental disclosure of cash flow information
Cash paid for interest				0		226
ROU asset acquired through operating leases				0		5,148
Unrealized loss on marketable securities				512		0
Acquisition of Trigr Therapeutics, Inc.				0		50,300
Fixed asset costs included in accounts payable				77		0
Purchase of securities included in accrued expenses				$ 513		$ 0